The most common grade @ or worse adverse events were rash ( @ -LSB- @ % -RSB- patients in the erlotinib plus bevacizumab group vs @ -LSB- @ % -RSB- patients in the erlotinib alone group ) , hypertension ( @ -LSB- @ % -RSB- vs eight -LSB- @ % -RSB- ) , and proteinuria ( six -LSB- @ % -RSB- vs none ) .